Recruiting

Lumateperone

Sponsor:

Massachusetts General Hospital

Code:

NCT07699445

Conditions

Bipolar Depression Depressed Phase

Obesity & Overweight

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Lumateperone 42 mg

Study Details

Brief summary:

This research study examines how a medication called lumateperone may affect mood symptoms, and inflammation in adults with bipolar disorder over approximately 6 weeks. An MRI scan to calculate biological age of the brain will also be obtained at the start of the study.

Conditions

Bipolar Depression Depressed Phase

Obesity & Overweight

Study ID

NCT07699445

Start date

Sep 9, 2026

Status verified date

Sep, 2026

Completion date

Jul 31, 2028

Anticipated

Primary completion date

Jan 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Aged 18 to 65 years.
2. Meets DSM-V criteria for Bipolar I Disorder -Depressed without psychosis as confirmed by a semi-structured clinical interview that includes the Mini International Neuropsychiatric Interview.
3. Current episode at least 4 weeks in duration but not longer than 12 months.
4. Depression score > 20 on the Montgomery Asberg Depression Rating Scale (MADRS).
5. BMI > 30
6. Capable of providing informed consent.

Exclusion Criteria:

1. Meets DSM-V criteria for Schizophrenia, Schizoaffective disorder, or has significant mood-incongruent psychotic symptoms.
2. Young Mania Rating Scale score >12.
3. Meets DSM-V criteria for rapid cycling.
4. Co-Morbid psychiatric illness, other than generalized anxiety and specific phobias, that in the opinion of the investigator is severe enough that it would likely interfere with the interpretation of changes in the subject's mood state.
5. Meets DSM-V criteria for an active substance use disorder within the past month.
6. Active medical condition that in the opinion of the investigator would contribute to the subject's depressed mood (e.g. hypothyroidism).
7. Significant risk of suicide or self -harm as assessed by clinical interview and the Columbia Suicide Severity Rating Scale (C-SSRS).
8. Significant risk of harm to others as assessed by clinical interview.
9. Pregnancy, or, in women of child-bearing potential, an unwillingness to use an accepted method of birth control for the duration of the study.
10. Current or prior treatment with lumateperone.
11. Moderate or severe hepatic impairment.
12. Current treatment with strong or moderate CYP3A4 inhibitors or CYP3A4 inducers.
13. History of seizure disorder.
14. Significant cardiovascular or cerebrovascular disease that, in the opinion of the investigator, would increase study risk.
15. Dementia-related psychosis.
16. Known hypersensitivity or allergy to lumateperone or any of its components.

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Lumateperone treatment

Lumateperone treatment for Bipolar type I depression

Interventions

Lumateperone 42 mg

Lumateperone 42 mg orally daily

Primary outcome measure

  • MADRS [ Time Frame: 6 week ]
  • Inflammatory Markers [ Time Frame: 6 weeks ]

Central Contacts and Locations

Central contacts

Locations

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

More Information

Sponsor

Massachusetts General Hospital

Last update posted

Sep 11, 2026

Last verified

Sep, 2026

Keywords

  • Bipolar disorder
  • Depression
  • obesity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-12. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-09-11.